Stock Market Update - January 12, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. EVTV - Envirotech Vehicles, Inc.
Price: $2.51 | Change: +442.00% ($2.0469)
EVTV has absolutely skyrocketed with an incredible 442.00% gain! This massive surge for Envirotech Vehicles, Inc. isn't because of electric vehicles, but rather a dramatic strategic pivot towards artificial intelligence infrastructure.
The company announced a proposed $480 million acquisition of AZIO AI Corporation, aiming to transform EVTV from an EV maker into an AI data center and high-performance computing powerhouse. This potential deal, which would make AZIO AI a wholly-owned subsidiary, has set the stage for a completely new direction for the company.
Adding significant fuel to the excitement, AZIO AI recently secured a binding purchase order for 256 Nvidia B300 GPUs, representing approximately $107 million in contractual revenue from a major governmental order. They also hinted at an additional $200 million regional pipeline. This immediate revenue-generating potential from the AI venture underscores the ambitious and potentially lucrative shift for EVTV, though the acquisition still awaits final agreements and approvals.
2. VXRT - Vaxart, Inc.
Price: $0.8 | Change: +109.86% ($0.4188)
VXRT stock rocketed an impressive 109.86% around January 13, 2026. This significant jump was largely driven by Vaxart's participation in the Global BioInnovation Forum on that date, where its senior leadership team, including the CEO, Chief Scientific Officer, and Chief Medical Officer, presented to the industry.
Investors were keenly anticipating positive updates regarding the company's pipeline of oral recombinant pill vaccines. Vaxart is developing candidates for major illnesses like COVID-19, norovirus, and influenza, as well as a therapeutic vaccine for HPV. Their oral vaccine platform is a key differentiator, offering potential benefits such as easy administration and room-temperature stability.
This heightened interest wasn't a one-day event; the stock had already surged over 92% in the two weeks leading up to the forum, accompanied by significantly elevated trading volume. The market appears to be speculating on the possibility of favorable clinical data or new partnership announcements emerging from this high-profile industry gathering.
3. LVLU - Lulu's Fashion Lounge Holdings, Inc.
Price: $12.15 | Change: +79.47% ($5.38)
LVLU:NASDAQ saw a remarkable 79.47% gain, largely thanks to a new player in town.
The surge came after activist investor Friedland Enterprises disclosed a 5% stake in Lulu's Fashion Lounge Holdings. Friedland argued that LVLU shares were "significantly undervalued" compared to its peers, despite the company's recent financial improvements. To unlock this perceived value, they proposed an eight-point plan, pushing for major changes from board reconstitution to exploring strategic alternatives like a potential sale or merger.
This event highlights the powerful influence activist investors can have. Their public challenge and detailed plan for corporate governance and operational reforms immediately sparked investor confidence, sending LVLU's stock soaring as the market reacted to the prospect of significant change and a potential turnaround.
4. ZVSA - ZyVersa Therapeutics, Inc.
Price: $0.221 | Change: +75.82% ($0.0953)
ZVSA experienced a significant surge, jumping 75.82%, as investors refocused on the biopharmaceutical company's clinical pipeline advancements. This notable upward movement appears largely driven by a substantial new financing agreement that provides critical capital for its drug development programs.
A key catalyst was a Share Purchase Agreement that provides ZyVersa with access to up to $10 million in funding. This capital is crucial for advancing its Cholesterol Efflux Mediator™ VAR 200, a drug candidate in Phase 2a trials designed to treat chronic kidney diseases. For a clinical-stage company, securing such funding is vital to continue research and development.
What makes this particularly interesting is the company's dual pipeline progress. Beyond VAR 200, ZyVersa is also preparing to initiate a first-in-human Phase 1 trial for its Inflammasome ASC Inhibitor IC 100 for inflammatory conditions in early 2026. This combination of secured financing and promising clinical milestones is likely fueling recent investor optimism.
5. PELIR - Pelican Acquisition Corporation Right
Price: $0.5913 | Change: +55.61% ($0.2113)
PELIR just surged an impressive 55.61% as its underlying merger to form Greenland Energy Company nears completion. Pelican Acquisition Corporation is set to combine with Greenland Exploration Limited and March GL Company, and the market is buzzing with anticipation for this new venture.
A major driver behind this excitement is the discovery of an estimated 13 billion barrels of potential oil reserves in Greenland's Jameson Land Basin, which the combined company will control. With the shareholder vote for the pivotal merger scheduled for January 20th and the transaction expected to close shortly thereafter, investors are reacting strongly to the potential of this future energy player. The new entity, Greenland Energy Company, is slated to trade on NASDAQ under the ticker symbol "GLND" with an implied valuation of $215 million.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.